newsCiliary Neurotrophic FactorMacular Telangiectasia Type 2
NT-501 Encapsulated Cell Therapy Successfully Slows Photoreceptor Loss in Macular Telangiectasia Type 2: Results from Two Phase 3 Trials
By MedXY|Dec 31, 2025
Two Phase 3 trials show that NT-501 encapsulated cell therapy significantly reduces ellipsoid zone area loss in Macular Telangiectasia Type 2. While functional outcomes were inconsistent, the treatment demonstrated a robust neuroprotective
